About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Cross-talk Between Statins and the Renin-angiotensin System

Citation:

Asia-Pacific Cardiology 2011;3(1):33–6

Atherosclerosis - The Future Challenge for Europe's Health Economies

Citation:

European Cardiology 2009;5(2):86–8

Cardiovascular Risk Assessment and Primary Prevention in the Era of Plaque Imaging

Citation:

European Cardiology 2008;4(1):12–6

Treatment Strategies for Patients with Acute Carotid Syndromes

Citation:

US Cardiology 2009;6(2):84–6